JP2012518164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518164A5 JP2012518164A5 JP2011549604A JP2011549604A JP2012518164A5 JP 2012518164 A5 JP2012518164 A5 JP 2012518164A5 JP 2011549604 A JP2011549604 A JP 2011549604A JP 2011549604 A JP2011549604 A JP 2011549604A JP 2012518164 A5 JP2012518164 A5 JP 2012518164A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- platinum
- rbm3
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SE2009/000091 WO2009102261A1 (en) | 2008-02-15 | 2009-02-16 | Rbm3 as a marker for breast cancer prognosis |
| SEPCT/SE2009/000091 | 2009-02-16 | ||
| US16996309P | 2009-04-16 | 2009-04-16 | |
| EP09158084.5 | 2009-04-16 | ||
| EP09158084A EP2241889A1 (en) | 2009-04-16 | 2009-04-16 | RBM3 protein in colorectal cancer prognostics |
| US61/169,963 | 2009-04-16 | ||
| US23376909P | 2009-08-13 | 2009-08-13 | |
| EP09167847A EP2293070A1 (en) | 2009-08-13 | 2009-08-13 | Means and methods for ovarian cancer prognosis |
| US61/233,769 | 2009-08-13 | ||
| EP09167847.4 | 2009-08-13 | ||
| PCT/EP2009/067419 WO2010091763A1 (en) | 2009-02-16 | 2009-12-17 | Rbm3 as a marker for malignant melanoma prognosis |
| EPPCT/EP2009/067419 | 2009-12-17 | ||
| PCT/EP2010/051941 WO2010092190A2 (en) | 2009-02-16 | 2010-02-16 | Prediction of response to platinum-based therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518164A JP2012518164A (ja) | 2012-08-09 |
| JP2012518164A5 true JP2012518164A5 (https=) | 2013-04-04 |
| JP5767116B2 JP5767116B2 (ja) | 2015-08-19 |
Family
ID=41718882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549601A Expired - Fee Related JP5611986B2 (ja) | 2009-02-16 | 2010-02-16 | 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質 |
| JP2011549603A Expired - Fee Related JP5669757B2 (ja) | 2009-02-16 | 2010-02-16 | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 |
| JP2011549604A Expired - Fee Related JP5767116B2 (ja) | 2009-02-16 | 2010-02-16 | 白金に基づく治療に対する応答の予測 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549601A Expired - Fee Related JP5611986B2 (ja) | 2009-02-16 | 2010-02-16 | 結腸直腸癌の予後診断におけるｒｂｍ３タンパク質 |
| JP2011549603A Expired - Fee Related JP5669757B2 (ja) | 2009-02-16 | 2010-02-16 | 精巣癌診断および予後診断におけるｒｂｍ３タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8632984B2 (https=) |
| EP (4) | EP2396657B1 (https=) |
| JP (3) | JP5611986B2 (https=) |
| CN (1) | CN102334032B (https=) |
| AU (4) | AU2009339802B2 (https=) |
| CA (3) | CA2749350A1 (https=) |
| DK (2) | DK2396660T3 (https=) |
| WO (5) | WO2010091763A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8632984B2 (en) * | 2009-02-16 | 2014-01-21 | Atlas Antibodies Ab | RBM3 as a marker for malignant melanoma prognosis |
| EP2524928A1 (en) | 2011-05-18 | 2012-11-21 | Atlas Antibodies AB | RBM3 in bladder cancer |
| CA2818593A1 (en) * | 2010-10-22 | 2012-04-26 | Vermillion, Inc. | Prognostic biomarkers in patients with ovarian cancer |
| US20120288480A1 (en) * | 2011-02-22 | 2012-11-15 | Taipei Medical University | Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications |
| EP2573566A1 (en) | 2011-09-20 | 2013-03-27 | Atlas Antibodies AB | RBM3 in prostate cancer prognostics |
| CN102590185B (zh) * | 2012-01-11 | 2013-12-25 | 东南大学 | 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法 |
| WO2016004387A1 (en) * | 2014-07-02 | 2016-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene expression signature for cancer prognosis |
| EP3023791A1 (en) * | 2014-11-21 | 2016-05-25 | Atlas Antibodies AB | Predicting the responsiveness to gemcitabine treatment |
| CN106611094B (zh) * | 2015-10-15 | 2021-08-06 | 北京寻因生物科技有限公司 | 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统 |
| CN113373151B (zh) * | 2021-06-30 | 2022-05-03 | 华中科技大学同济医学院附属协和医院 | 环状RNAhsa_circ_0008399的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| GB9917027D0 (en) | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US6686155B2 (en) * | 2001-06-14 | 2004-02-03 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression |
| WO2006071896A2 (en) * | 2004-12-23 | 2006-07-06 | The Hong Kong University Of Science And Technology | Epitope-based sars vaccine |
| EP1934867A2 (en) | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2008051260A1 (en) | 2006-01-13 | 2008-05-02 | Battelle Memorial Institute | Methods for assessing copd-retlated diseases |
| EP1862803A1 (en) * | 2006-06-02 | 2007-12-05 | Atlas Antibodies AB | Use of protein SATB2 as a marker for colorectal cancer |
| EP2090890A1 (en) * | 2008-02-15 | 2009-08-19 | Atlas Antibodies AB | RBM3 as a marker for breast cancer prognosis |
| US7902166B2 (en) * | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
| US8632984B2 (en) * | 2009-02-16 | 2014-01-21 | Atlas Antibodies Ab | RBM3 as a marker for malignant melanoma prognosis |
| EP2524928A1 (en) * | 2011-05-18 | 2012-11-21 | Atlas Antibodies AB | RBM3 in bladder cancer |
-
2009
- 2009-12-17 US US13/201,742 patent/US8632984B2/en not_active Expired - Fee Related
- 2009-12-17 AU AU2009339802A patent/AU2009339802B2/en not_active Ceased
- 2009-12-17 EP EP09803750.0A patent/EP2396657B1/en not_active Not-in-force
- 2009-12-17 WO PCT/EP2009/067419 patent/WO2010091763A1/en not_active Ceased
-
2010
- 2010-02-16 US US13/201,689 patent/US8747910B2/en not_active Expired - Fee Related
- 2010-02-16 EP EP10705141A patent/EP2396346B1/en not_active Not-in-force
- 2010-02-16 US US13/201,740 patent/US20120058202A1/en not_active Abandoned
- 2010-02-16 JP JP2011549601A patent/JP5611986B2/ja not_active Expired - Fee Related
- 2010-02-16 CA CA2749350A patent/CA2749350A1/en not_active Abandoned
- 2010-02-16 WO PCT/EP2010/051935 patent/WO2010092187A1/en not_active Ceased
- 2010-02-16 EP EP10704928.0A patent/EP2396660B1/en not_active Not-in-force
- 2010-02-16 DK DK10704928.0T patent/DK2396660T3/da active
- 2010-02-16 CA CA2749349A patent/CA2749349A1/en not_active Abandoned
- 2010-02-16 WO PCT/EP2010/051917 patent/WO2010092182A1/en not_active Ceased
- 2010-02-16 CN CN201080007960.0A patent/CN102334032B/zh not_active Expired - Fee Related
- 2010-02-16 AU AU2010212772A patent/AU2010212772B2/en not_active Ceased
- 2010-02-16 AU AU2010212769A patent/AU2010212769C1/en not_active Ceased
- 2010-02-16 CA CA2749392A patent/CA2749392A1/en not_active Abandoned
- 2010-02-16 DK DK10704927.2T patent/DK2396659T3/da active
- 2010-02-16 WO PCT/EP2010/051941 patent/WO2010092190A2/en not_active Ceased
- 2010-02-16 WO PCT/EP2010/051920 patent/WO2010092184A1/en not_active Ceased
- 2010-02-16 JP JP2011549603A patent/JP5669757B2/ja not_active Expired - Fee Related
- 2010-02-16 JP JP2011549604A patent/JP5767116B2/ja not_active Expired - Fee Related
- 2010-02-16 AU AU2010212764A patent/AU2010212764B2/en not_active Ceased
- 2010-02-16 EP EP10704927A patent/EP2396659B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518164A5 (https=) | ||
| ES3063063T3 (en) | Method of predicting cancer prognosis and composition for same | |
| Friedländer et al. | ErbB-directed immunotherapy: antibodies in current practice and promising new agents | |
| JP2012518163A5 (https=) | ||
| JP2014521308A5 (https=) | ||
| JP2012518162A5 (https=) | ||
| NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
| ES3023842T3 (en) | Methods for prostate cancer detection and treatment | |
| Li et al. | Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| WO2010000907A1 (es) | Huella genómica de cáncer de mama | |
| JP7724265B2 (ja) | 遺伝子発現アッセイを使った予測ペプチド受容体放射性核種療法 | |
| Yin et al. | Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients | |
| Feldman | Update in germ cell tumours | |
| Xu et al. | ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer | |
| JP2011527575A5 (https=) | ||
| EP4186006A1 (en) | A deep learning framework to identify pathogenic non-coding somatic mutations from personal cancer genomes | |
| Luo et al. | Sensitive small extracellular vesicles associated circRNAs analysis combined with machine learning for precision identification of gastric cancer | |
| JP2014517282A5 (https=) | ||
| JP2023500819A5 (https=) | ||
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Ji et al. | Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5, 10-methylenetetrahydrofolate reductase (5, 10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer | |
| Harris et al. | Quest for the ideal cancer biomarker: an update on progress in capture and characterization of circulating tumor cells | |
| KR20220087022A (ko) | 뇌종양 진단 또는 예후 예측용 용질 운반체 바이오마커 조성물 | |
| CN105861681A (zh) | 用于肺癌EGFR基因Sanger测序前样品质控的分子指标、试剂盒及方法 |